Patient Experiences of Intravitreal Anti-Vascular Endothelial Growth Factor Injections for Age-Related Macular Degeneration: A Meta-Synthesis of Qualitative Studies Authors: Dong Liu, HaiYan Bi, Ying Sun, ZiQian Gao, Ping Lu Published: 2026 ABSTRACT AimTo synthesize evidence from qualitative studies on patients receiving intravitreal anti-vascular endothelial growth factor injections for age-related macular degeneration to explore their treatment burdens and life experiences.MethodsFive databases (PubMed, Web of Science, Embase, Cochrane Library, and CINAHL) were searched on 20 May 2025, with supplementation through hand-searching. The search was restricted to qualitative or mixed-methods studies published in English. The included studies were evaluated and synthesized by two independent reviewers using the Joanna Briggs Institute (JBI) critical appraisal tools and the JBI aggregative integration method.ResultsThirteen studies (2010–2023) from 11 countries were summarized into four themes: barriers to treatment and sources of anxiety, coping strategies and adaptation mechanisms, drivers of treatment adherence, and the impact of doctor-patient engagement.ConclusionPatients with age-related macular degeneration face significant physical, emotional, and logistical challenges during anti-vascular endothelial growth factor therapy. A series of measures can be integrated into the treatment process to improve patient adherence, including psychological support, structured patient education, and optimized treatment pathways.RegistrationPROSPERO CRD420251059151. Introduction Age-related macular degeneration (AMD) is a prevalent, degenerative disease that affects the retina, retinal pigment epithelium (RPE), and choriocapillaris, resulting in central vision loss.1 AMD is a leading cause of severe vision loss globally, particularly in developed countries, with one study reporting a higher prevalence in Europeans compared to both Asian and African populations. With an estimated 196 million people affected in 2020, a figure projected to rise to 288 million by 2040.2 Currently, AMD is the third leading cause of global vision loss, after cataracts and uncorrected refractive errors,3 and is most likely the frequent cause of blindness in older adults. The late AMD prevalence increases log-linearly with an average four-fold increase per decade after 50, which has a significant public health burden.4 Intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF), including ranibizumab,5 aflibercept,6 and bevacizumab,7 has demonstrated efficacy in treating AMD and significantly improves vision. This therapeutic effect is achieved by specifically inhibiting VEGF activity, which suppresses the formation and leakage of neovascular vessels. However, this treatment imposes a substantial burden on patients, as it requires frequent, long-term injections to maintain therapeutic benefits. An AMD treatment regimen involves monthly injections until “stable” for 3–4 consecutive months, followed by a maintenance phase individualized to the patient’s needs (treat and extend or pro re nata regimen).8 The clinical benefits of anti-VEGF treatment are well established and understood, however, there is comprehensive evidence of patients’ experiences of this demanding treatment regimen. Furthermore, evidence shows that patients undergoing treatment with intravitreal injections for AMD have multiple burdens that extend beyond the physical aspects of treatment. Some studies documented a few repeating themes: surgery-related anxieties (pain), duration of unpredictable treatment periods and the burdensome time and cost of ongoing care.9–11 Patients report distinct experiences based on treatment frequency, injection technique and quality of communication between patient and provider. Although awareness of these issues is growing in the literature, it is only in recent years that researchers have begun to use qualitative data from small studies, and quantify patient-reported outcomes (PROs), and attempt to synthesize research in different medical and cultural contexts.12 This study aims to explore the experiences of patients receiving intravitreal anti-VEGF injections for AMD. Prior research type is either quantitative or qualitative. Moreover, prior systematic reviews or meta-syntheses have often included studies whose participants were limited to those diagnosed with AMD but not necessarily receiving anti-VEGF therapy. A qualitative meta-synthesis on patients receiving intravitreal anti-VEGF injections for AMD can integrate these diverse findings. This approach overcomes the limited depth and flexibility of previous methodologies, generating novel themes that yield critical insights into real-world patient experiences and guide meaningful advancements in care. Methods This comprehensive search was conducted across five databases (PubMed, Web of Science, Embase, Cochrane Library, and CINAHL), supplemented by additional resources obtained through hand-searching, covering records from their inception to May 2025 using a predefined search strategy. The search strategy combined Medical Subject Headings (MeSH) and free-text keywords related to: age-related macular degeneration, AMD; intravitreal injections, intraocular injection; anti-VEGF, anti-vascular endothelial growth factor; perception, emotions, attitude, experience, feelings, expectations, needs, psychological, mental, difficulties, burdens, barriers, obstacles; qualitative research, grounded theory, focus groups, observation, qualitative study, phenomenology, interview, ethnography, recognizing treatment discontinuation as a meaningful indicator of patient attitudes, we specifically included terms such as discontinuation,13 nonadherence or nonpersistence,14 dropout.15 The search strategy with PubMed as an example is presented in Box 1. Box 1Search Strategy Used in PubMed Database. The Search Combined Medical Subject Headings (MeSH) and Free-Text Keywords Related to Age-Related Macular Degeneration, Intravitreal Injections, Anti-Vascular Endothelial Growth Factor (Anti-VEGF), Patient Experiences and Attitudes, and Qualitative Research Methodologies#1 “age-related macular degeneration” [Title/Abstract] OR “AMD” [Title/Abstract]#2 “intravitreal injections” [MeSH Terms] OR “intraocular injection” [Title/Abstract] OR “anti-VEGF” [Title/Abstract] OR “anti-vascular endothelial growth factor” [Title/Abstract]#3 “perception” [MeSH Terms] OR “emotions” [MeSH Terms] OR “attitude” [MeSH Terms] OR “experience” [Title/Abstract] OR “feelings” [Title/Abstract] OR “expectations” [Title/Abstract] OR “needs” [Title/Abstract] OR “psychological” [Title/Abstract] OR “mental” [Title/Abstract] OR “difficulties” [Title/Abstract] OR “burdens” [Title/Abstract] OR “barriers” [Title/Abstract] OR “obstacles” [Title/Abstract] OR “discontinuation” [Title/Abstract] OR “nonadherence” [Title/Abstract] OR “nonpersistence” [Title/Abstract] OR “dropout” [Title/Abstract]#4 “qualitative research” [MeSH Terms] OR “grounded theory” [MeSH Terms] OR “focus groups” [MeSH Terms] OR “observation” [MeSH Terms] OR “qualitative study” [Title/Abstract] OR “phenomenology” [Title/Abstract] OR “interview” [Title/Abstract] OR “ethnography” [Title/Abstract]#5 #1 AND #2 AND #3 AND #4 Box 1Search Strategy Used in PubMed Database. The Search Combined Medical Subject Headings (MeSH) and Free-Text Keywords Related to Age-Related Macular Degeneration, Intravitreal Injections, Anti-Vascular Endothelial Growth Factor (Anti-VEGF), Patient Experiences and Attitudes, and Qualitative Research Methodologies#1 “age-related macular degeneration” [Title/Abstract] OR “AMD” [Title/Abstract]#2 “intravitreal injections” [MeSH Terms] OR “intraocular injection” [Title/Abstract] OR “anti-VEGF” [Title/Abstract] OR “anti-vascular endothelial growth factor” [Title/Abstract]#3 “perception” [MeSH Terms] OR “emotions” [MeSH Terms] OR “attitude” [MeSH Terms] OR “experience” [Title/Abstract] OR “feelings” [Title/Abstract] OR “expectations” [Title/Abstract] OR “needs” [Title/Abstract] OR “psychological” [Title/Abstract] OR “mental” [Title/Abstract] OR “difficulties” [Title/Abstract] OR “burdens” [Title/Abstract] OR “barriers” [Title/Abstract] OR “obstacles” [Title/Abstract] OR “discontinuation” [Title/Abstract] OR “nonadherence” [Title/Abstract] OR “nonpersistence” [Title/Abstract] OR “dropout” [Title/Abstract]#4 “qualitative research” [MeSH Terms] OR “grounded theory” [MeSH Terms] OR “focus groups” [MeSH Terms] OR “observation” [MeSH Terms] OR “qualitative study” [Title/Abstract] OR “phenomenology” [Title/Abstract] OR “interview” [Title/Abstract] OR “ethnography” [Title/Abstract]#5 #1 AND #2 AND #3 AND #4 Search Strategy Used in PubMed Database. The Search Combined Medical Subject Headings (MeSH) and Free-Text Keywords Related to Age-Related Macular Degeneration, Intravitreal Injections, Anti-Vascular Endothelial Growth Factor (Anti-VEGF), Patient Experiences and Attitudes, and Qualitative Research Methodologies Inclusion and Exclusion This section is structured according to the PICoS framework,16 the inclusion criteria for the studies included: patients with any type of age-related macular degeneration (AMD) undergoing intravitreal anti-VEGF injections (Population). Studies must focus on patient’ experiences, attitude, difficulties, emotions, coping strategies, treatment burdens (Phenomenon of Interest). The context is limited to clinical or outpatient settings where anti-VEGF injections are administered (Context). Only qualitative studies (eg, phenomenology, grounded theory) or mixed-methods studies with substantial qualitative data will be included (Study Design). Studies will be excluded if they are duplicate publications, have no full text, are published in languages other than English, or poorly documented research procedures that compromise the validity of findings. Study Selection and Data Extraction Two researchers (D.L. and H.Y.B.) independently screened the literature initially, with any disagreements resolved through discussion with a third researcher (Y.S) to reach consensus. Using the EndNote software system, duplicate records were first removed. Studies were initially selected based on their titles and abstracts, followed by a full-text review to confirm final inclusion. For each included study, the author(s), year of publication, country, participants, research methodology, phenomenon of interest and key findings were extracted. Quality Appraisal All the studies included were independently evaluated by two researchers (D.L. and H.Y.B.) using Joanna Briggs Institute (JBI) critical appraisal tools. The checklist includes 10 items, each rated as “yes”, “no”, “unclear” or “not applicable”. Studies that meet ≥7 criteria were classified as high-quality evidence, any disagreements during assessment were resolved through discussion with a third researcher (Y.S.) until a consensus was reached. The evaluation process is illustrated in Table 1. Table 1Literature Quality Appraisal Form. Quality Appraisal of Included Studies Using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Qualitative Research. The Table Presents the Scoring of Each Study Against the 10 Checklist Criteria (Rated as Yes, No, Unclear, or Not Applicable). Studies Meeting 7 or More Criteria Were Classified as High-Quality EvidenceReferenceQ1Q2Q3Q4Q5Q6Q7Q8Q9Q10Result (%)Giocanti-Auregan et al17YYYYYNNYYY80%Midena et al18YYYYYNNYYY80%Burton et al19YYYYYNNYUY70%Thetford et al20YYYYYNNYYY80%McCloud et al21YYYYYNYYYY90%Yiallouridou et al22YYYYYNNYYY80%McCloud et al23YYYYYNNYYY80%Thier et al24YYYYYYNYYY90%Talks et al25YYYYYNNYYY80%Thinggaard et al26YYYYYYYYYY100%Bian et al27YYYYYNYYYY90%Kristina et al28YYYYYNNYUY70%Enoch et al29YYYYYNNYYY80%Abbreviations: Q, Question; Y, yes; N, no; U, unclear. Table 1Literature Quality Appraisal Form. Quality Appraisal of Included Studies Using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Qualitative Research. The Table Presents the Scoring of Each Study Against the 10 Checklist Criteria (Rated as Yes, No, Unclear, or Not Applicable). Studies Meeting 7 or More Criteria Were Classified as High-Quality EvidenceReferenceQ1Q2Q3Q4Q5Q6Q7Q8Q9Q10Result (%)Giocanti-Auregan et al17YYYYYNNYYY80%Midena et al18YYYYYNNYYY80%Burton et al19YYYYYNNYUY70%Thetford et al20YYYYYNNYYY80%McCloud et al21YYYYYNYYYY90%Yiallouridou et al22YYYYYNNYYY80%McCloud et al23YYYYYNNYYY80%Thier et al24YYYYYYNYYY90%Talks et al25YYYYYNNYYY80%Thinggaard et al26YYYYYYYYYY100%Bian et al27YYYYYNYYYY90%Kristina et al28YYYYYNNYUY70%Enoch et al29YYYYYNNYYY80%Abbreviations: Q, Question; Y, yes; N, no; U, unclear. Literature Quality Appraisal Form. Quality Appraisal of Included Studies Using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Qualitative Research. The Table Presents the Scoring of Each Study Against the 10 Checklist Criteria (Rated as Yes, No, Unclear, or Not Applicable). Studies Meeting 7 or More Criteria Were Classified as High-Quality Evidence Abbreviations: Q, Question; Y, yes; N, no; U, unclear. Synthesis All the studies included were systematically synthesized following the Joanna Briggs Institute (JBI) methodology for comprehensive integration to ensure a rigorous evidence synthesis process. The process involved extracting and arranging data, grouping similar findings, and integrating conclusions without reinterpretation, to provide the best opportunity thereby preserving the original meaning.30 Results Search Results The initial search identified 587 articles from multiple databases. After removing 98 duplicate records, 489 articles proceeded to title and abstract screening, excluding 442 irrelevant studies, full-text review of 47 articles applied strict inclusion criteria, excluding 34 publications for: ineligible populations, inappropriate study design, non-English language, unavailable full-texts and poor methodological quality. This search process is illustrated in Figure 1. Thirteen qualifying studies (2010–2023) from 11 countries were included: USA (n=1), Canada (n=1), France (n=2), Italy (n=2), Germany (n=3), Spain (n=1), UK (n=5), Australia (n=2), Denmark (n=1), China (n=1) and Sweden (n=1). Characteristics of included studies are presented in Table 2. Table 2Characteristics of Included Studies. The Table Summarizes the Author(s), Year of Publication, Country, Participant Characteristics, Research Methodology, Phenomenon of Interest, and Key Findings for Each Study Included in the Meta-SynthesisAuthor, Year, CountryParticipantsResearch MethodologyPhenomenon of InterestsKey FindingsGiocanti-Auregan et al, 2022,17 six countries (USA, Canada, France, Italy, Germany, Spain)N=49, female=37, male=12, aged>70 (69%)Grounded theory, semi-structured interviewsTo understand treatment experiences, drivers and barriers to adherence in nAMD from patients’Five themes: disease experience, anti-VEGF intravitreal injections experience, adherence to anti-VEGF intravitreal injections, drivers for following management plan (adherence), barriers to following management plan (adherence)Midena et al, 2022,18 ItalyN=163, female=101, male=62, aged (mean) 76Narrative medicine, semi-structured interviewsTo explore the experience of patients affected by nAMD in the healthcare pathway for the management of the diseaseFour themes: from symptoms to access to care, reaction to diagnosis of nAMD, treatment and perception of efficacy, impact on quality of lifeBurton et al, 2013,19 UKN=7, female=5, male=2, aged (mean) 82Interpretive phenomenological study, semi-structured interviewsTo explore the experiences of AMD patients treated with intravitreal ranibizumab injectionsFour themes: preparing for treatment, the treatment process, health-care professional–patient communication, results of treatmentThetford et al, 2013,20 UKN=22, female=13, male=9, aged (mean) 77Biographical narrative interpretive approach, qualitative narrative interviewsTo explore access to treatment, the experience of undergoing assessments, expectations of the procedure and the treatment outcome, and actual experiences of, and feelings about, receiving treatmentFour themes: anxiety and fear of the ‘unknown’, injection procedure, side effects, service deliveryMcCloud et al, 2015,21 AustraliaN=25, female=13, male=12, aged (mean) 83Interpretivephenomenological analysis, unstructured interviewsTo understand the participant’ s experience of neovascular AMD, including ongoing treatment with anti-VEGFTwo themes: a life negotiated by neovascular AMD, uncertaintyYiallouridou et al, 2023,22 UKN=14, female=9, male=5, aged (mean) 82.5In-depth qualitative approach, semi-structured interviewsTo identify key variations in treatment procedures that may influence pain, and to gain insights into the post-injection experience and treatment adherenceThree themes: fear of losing eyesight and treatment anxiety influence patient adherence to treatment, variability in pain experience during treatment, post-injection experience and impact on patient recoveryMcCloud et al, 2014,23 AustraliaN=34, female=19, male=15, aged (mean) 81Interpretive qualitative methodology, focus group, semi-structured interviewsTo understand people’ s experience with age-related macular degeneration (AMD) in light of new treatment successesFour themes: cautious optimism, enduring, adaptation, profound lossThier et al, 2022,24 GermanyN=22, female=14, male=8, aged 70-95Grounded theory, narrative, semi-structured interviewsTo better understand the continued barriers to the provision of anti-VEGF therapyFour themes: physical experiences, emotional experiences, communication and interactions with doctors and medical staff, dealing with the injectionsTalks et al, 2023,25 three countries (Germany, France, UK)N=17, female=9, male=8, aged (mean) 77Qualitative methodology, semi-structured interviewsTo understand emotions and experiences of patients with nAMD may help inform the determinants of adherenceFour themes: from visual concerns to diagnosis and initial treatment, treatment, clinical management of nAMD, the impact of nAMDThinggaard et al, 2023,26 DenmarkN=21, female=15, male=6, aged (mean) 79Gadamer’ s hermeneutics approach, semi-structured or dyadic interviewsTo investigate patient-reported barriers to the recommended treatment for nAMD and their impact on quality of lifeFive themes: good compliance with intravitreal treatment, the dual role of relatives, treatment commute, hospital barriers, preventive health literacyBian et al, 2019,27 ChinaN=21, female=16, male=5, aged (mean) 64Qualitative descriptive study, semi-structured interviewsTo investigate the experience of patients with wet age-related macular degeneration (wAMD) in treatment decision-making processFour themes: facing the darkness, constraints on decision making, weighing alternatives, decision making supportKristina et al, 2010,28 SwedenN=10, female=8, male=2, aged 66-95Phenomenological study, open-ended interviewsTo evaluate the patients’ experiences of intravitreal injections in AMDFour themes: information, fear/discomfort, subjective expectations regarding vision, confidence in the careEnoch et al, 2023,29 UKN=30, female=20, male=10, aged (mean) 83Framework analysis, semi-structured interviewsTo investigate the extent to which regular intravitreal injections may be acceptable to geographic atrophy patientsSeven themes: affective attitude, burden, ethicality, intervention coherence, opportunity costs, perceived effectiveness, self-efficacy Figure 1PRISMA flowchart of study selection. A total of 587 records were identified through database searching (n=585) and hand-searching (n=2). After removing 98 duplicate records, 489 articles were screened based on titles and abstracts. Following the exclusion of 442 irrelevant studies, 47 full-text articles were assessed for eligibility. A further 34 articles were excluded due to ineligible populations, inappropriate study design, non-English language, unavailable full-text, or poor methodological quality. Finally, 13 studies were included in the qualitative meta-synthesis.The flowchart illustrates the study selection process using the PRISMA method. In the identification stage, 585 records were found through database searching, including PubMed, Web of Science, Embase, Cochrane Library and CINAHL. Additionally, 2 records were identified through hand searching in specific journals. This resulted in 587 records identified through searching. In the screening stage, 98 duplicate records were removed, leaving 489 records to be screened by title and abstract. Of these, 442 records were excluded. The remaining 47 full-text articles were assessed for eligibility. In the inclusion stage, 34 articles were excluded due to reasons such as ineligible population, inappropriate study design, non-English language, unavailable full-text, or poor methodological quality. Finally, 13 studies were included in the qualitative synthesis.A PRISMA flowchart of study selection process with identification, screening and inclusion stages. Table 2Characteristics of Included Studies. The Table Summarizes the Author(s), Year of Publication, Country, Participant Characteristics, Research Methodology, Phenomenon of Interest, and Key Findings for Each Study Included in the Meta-SynthesisAuthor, Year, CountryParticipantsResearch MethodologyPhenomenon of InterestsKey FindingsGiocanti-Auregan et al, 2022,17 six countries (USA, Canada, France, Italy, Germany, Spain)N=49, female=37, male=12, aged>70 (69%)Grounded theory, semi-structured interviewsTo understand treatment experiences, drivers and barriers to adherence in nAMD from patients’Five themes: disease experience, anti-VEGF intravitreal injections experience, adherence to anti-VEGF intravitreal injections, drivers for following management plan (adherence), barriers to following management plan (adherence)Midena et al, 2022,18 ItalyN=163, female=101, male=62, aged (mean) 76Narrative medicine, semi-structured interviewsTo explore the experience of patients affected by nAMD in the healthcare pathway for the management of the diseaseFour themes: from symptoms to access to care, reaction to diagnosis of nAMD, treatment and perception of efficacy, impact on quality of lifeBurton et al, 2013,19 UKN=7, female=5, male=2, aged (mean) 82Interpretive phenomenological study, semi-structured interviewsTo explore the experiences of AMD patients treated with intravitreal ranibizumab injectionsFour themes: preparing for treatment, the treatment process, health-care professional–patient communication, results of treatmentThetford et al, 2013,20 UKN=22, female=13, male=9, aged (mean) 77Biographical narrative interpretive approach, qualitative narrative interviewsTo explore access to treatment, the experience of undergoing assessments, expectations of the procedure and the treatment outcome, and actual experiences of, and feelings about, receiving treatmentFour themes: anxiety and fear of the ‘unknown’, injection procedure, side effects, service deliveryMcCloud et al, 2015,21 AustraliaN=25, female=13, male=12, aged (mean) 83Interpretivephenomenological analysis, unstructured interviewsTo understand the participant’ s experience of neovascular AMD, including ongoing treatment with anti-VEGFTwo themes: a life negotiated by neovascular AMD, uncertaintyYiallouridou et al, 2023,22 UKN=14, female=9, male=5, aged (mean) 82.5In-depth qualitative approach, semi-structured interviewsTo identify key variations in treatment procedures that may influence pain, and to gain insights into the post-injection experience and treatment adherenceThree themes: fear of losing eyesight and treatment anxiety influence patient adherence to treatment, variability in pain experience during treatment, post-injection experience and impact on patient recoveryMcCloud et al, 2014,23 AustraliaN=34, female=19, male=15, aged (mean) 81Interpretive qualitative methodology, focus group, semi-structured interviewsTo understand people’ s experience with age-related macular degeneration (AMD) in light of new treatment successesFour themes: cautious optimism, enduring, adaptation, profound lossThier et al, 2022,24 GermanyN=22, female=14, male=8, aged 70-95Grounded theory, narrative, semi-structured interviewsTo better understand the continued barriers to the provision of anti-VEGF therapyFour themes: physical experiences, emotional experiences, communication and interactions with doctors and medical staff, dealing with the injectionsTalks et al, 2023,25 three countries (Germany, France, UK)N=17, female=9, male=8, aged (mean) 77Qualitative methodology, semi-structured interviewsTo understand emotions and experiences of patients with nAMD may help inform the determinants of adherenceFour themes: from visual concerns to diagnosis and initial treatment, treatment, clinical management of nAMD, the impact of nAMDThinggaard et al, 2023,26 DenmarkN=21, female=15, male=6, aged (mean) 79Gadamer’ s hermeneutics approach, semi-structured or dyadic interviewsTo investigate patient-reported barriers to the recommended treatment for nAMD and their impact on quality of lifeFive themes: good compliance with intravitreal treatment, the dual role of relatives, treatment commute, hospital barriers, preventive health literacyBian et al, 2019,27 ChinaN=21, female=16, male=5, aged (mean) 64Qualitative descriptive study, semi-structured interviewsTo investigate the experience of patients with wet age-related macular degeneration (wAMD) in treatment decision-making processFour themes: facing the darkness, constraints on decision making, weighing alternatives, decision making supportKristina et al, 2010,28 SwedenN=10, female=8, male=2, aged 66-95Phenomenological study, open-ended interviewsTo evaluate the patients’ experiences of intravitreal injections in AMDFour themes: information, fear/discomfort, subjective expectations regarding vision, confidence in the careEnoch et al, 2023,29 UKN=30, female=20, male=10, aged (mean) 83Framework analysis, semi-structured interviewsTo investigate the extent to which regular intravitreal injections may be acceptable to geographic atrophy patientsSeven themes: affective attitude, burden, ethicality, intervention coherence, opportunity costs, perceived effectiveness, self-efficacy Characteristics of Included Studies. The Table Summarizes the Author(s), Year of Publication, Country, Participant Characteristics, Research Methodology, Phenomenon of Interest, and Key Findings for Each Study Included in the Meta-Synthesis PRISMA flowchart of study selection. A total of 587 records were identified through database searching (n=585) and hand-searching (n=2). After removing 98 duplicate records, 489 articles were screened based on titles and abstracts. Following the exclusion of 442 irrelevant studies, 47 full-text articles were assessed for eligibility. A further 34 articles were excluded due to ineligible populations, inappropriate study design, non-English language, unavailable full-text, or poor methodological quality. Finally, 13 studies were included in the qualitative meta-synthesis. Barriers to Treatment and Sources of Anxiety Physiological and Procedure-Related Concerns Many patients experience anxiety about injection procedures, particularly during initial exposures when procedural uncertainty exists “It’s just the apprehension of not knowing, which adds to the tension and the nerves, and you know, the first time not knowing what the actual procedure is going to be knowing whether it is going to hurt”20 The associated pain and treatment-related discomfort often intensify this apprehension “And with every injection that I get – there is always fear…you never go there without fear, because it is in the eye …sometimes you do not even notice when they stick it in, right? And other times it cracks (very painful)”.24 In some cases, significant discomfort or unsatisfactory treatment responses may result in premature therapy discontinuation “And I am no longer willing to have the injection, because it’s very painful and second it has no effect Not better, not worse It’s stayed the same”.24 Psychological and Cognitive Challenges A proportion of patients demonstrate significant uncertainty regarding disease progression and treatment prognosis. “In another year, I do not know how it is going to be. So I do not know how long I can commit for treatment”.29 I really don’t know (if treatment works). Otherwise, I feel that it’s going pretty straightforward. Fortunately the vision hasn’t dropped that much. So you can’t really say that it’s helping. I don’t think it’s that great. 26 Other patients passively acquiesce to treatment due to insufficient understanding of their condition. “I simply get too little information. In terms of treatment, it may be good. But I just do not get enough information”,25 The doctor talked a lot, but I didn’t fully understand the information. I needed more time to digest the information and to consider whether my decision was correct.27 Furthermore, certain patients perceive their current visual acuity as adequate or maintain reserved expectations regarding therapeutic outcomes. “At the moment, I am quite happy…I can read the newspapers and everything. I feel much better. So, there’s no point in taking injections”.29 Process and Burden Considerations Prolonged waiting periods prior to injections represent a common patient concern. “Overall, I was very upset. Everywhere I went had long waiting lists, but then they tell us that months make a difference”,18 “You do [get] a bit fed up sitting down waiting for your name to be called, you know, it’s a hospital so you expect them things don’t you, you’ve got to wait, but you get a bit agitated”,20 The substantial treatment costs and associated caregiver burden create additional challenges. “The injection is too expensive, and it is such a big burden to a common person with average salary”, “my relatives have to spend more time to take care of me, and I have to consider their feelings”,27 It is worth noting that some patients reported that their treatment plans had led to lifestyle changes. “you gear your lifestyle around it… if we were wanting to go somewhere you just cannot go because of it”.21 Coping Strategies and Adaptation Mechanisms Positive Coping Developing predictable treatment patterns through repeated treatment. “you get used to them after a while”, “I tootle along, and I know exactly what’s going to happen and it does not bother me at all”.21 Alternatively, modifying expectations to foster realistic acceptance of clinical outcomes. “It’s an acceptance that it has to be done. It’s either that or the macular degeneration will continue”.21 Employing adaptive coping mechanisms to manage disease-induced alterations. “[My wife is] great. She knows I cannot stand the light. The home is in darkness when I am back at home”, “Carrots, lentils, that’s classical. Blueberries…good for vision. And the intern in the ER prescribed me a treatment to cure vision, not to cure nAMD, [but] vision. It is a food supplement with omega 3, lutein, zinc”.25 Negative Coping Patients abandoned hobbies and social activities due to illness or medical treatment. “We used to go away for the whole winter, so we could not any more…we just altered our lifestyle to suit”, “It seemed to put an end to lots of things in life, you know”.21 Drivers of Treatment Acceptance and Adherence Positive Attitudes and Cognition Some patients demonstrate comprehensive understanding of therapeutic outcomes and maintain realistic treatment expectations. “It is not treating it, it’s slowing it down, it’s slowing the deterioration down”, “As long as it [AMD] doesn’t return but if it returns hopefully the drugs will work again”.23 The quality of the doctor–patient relationship significantly affects the treatment attitude, and the positive interaction promotes greater treatment optimism. “The girl who does it is very good, I always have the same one who does my injections…She puts you at ease because I was terrible when I first came in. I am still dying a thousand deaths but I am braver”.29 Many patients successfully maintain independence through assistive devices, tailored lifestyle adjustments. “I have bought a Kindle e-reader for reading books and I can increase the size of the font if need be so that I can read them comfortably”.23 External Support System Family involvement serves as a powerful treatment motivation. “I have my children and at the moment my daughter driving me, making sure I get home again”.26 Peer support groups provide important psychological reassurance. “On the last treatment, there was [an] older lady, there with her husband and she was. [nervous] like you know, obviously, they said, “what’s it like”, and I said, “your first one”. I’d had two or three, and I said,’no, there’s no pain’I said, “it’s a funny sensation, and you feel a bit squeezy when you go in and you see the chair there, and you see them with the masks on”, that’s what frightens–frightens people I think. I said, “there’s a funny sensation, just a funny sensation’and’I said there’s no need to worry, no pain, definitely no pain”. She went in before me and when she come out her husband went, “thanks”, I said’it’s alright, it’s no problem’, and you know, I am glad I could have put somebody at ease”.19 The health insurance system ensures treatment accessibility. “Formerly, it cost an enormous amount of money. With my mother, the injection still cost around 1000 euros. Now I pay about 6–7 euros in addition to my health insurance[.]I would advise people not to be afraid”.25 Convenience Healthcare service accessibility significantly enhances patient acceptance of treatment regimens. “I do not mind to come in as many times as required. I live very close, 10 min [away]”, “I can get to the hospital quite easily. If my wife cannot do it, I have got close family that would do it so there’s no expense like taxis, et cetera”.29 Influence of Doctor-Patient Engagement Positive Impacts Therapeutic trust significantly enhances patients’ confidence in treatment efficacy. “I am confident in the doctor, I am confident in the treatment and have the support of my husband and you know we just do the best we can”,17 “It was a doctor who made a good impression on me immediately because he introduced himself first, we exchanged a few words. And afterwards he was also simply friendly, personable”.24 Negative Impacts Healthcare provider indifference or inadequate communication exacerbates negative emotions. “That was pretty horrible. I was lying on something, I could not see anything. Then there were four others lying next to me. And then those (medical staff) who were there, nobody said “hello”, nobody introduced themselves, no. That was pretty horrible…And then they (the medical staff) just talked among themselves. I found that, well, to be honest, I thought that was pretty creepy…So I really also thought, where am I, in a car repair shop or something? So not even perceived as a human”.24 Deficiencies in clinical proficiency lead to negative care encounters. “It’s true that my first eye doctor was quite ignorant, the injections were already available, but he did not prescribe them”, “When they mentioned macular disease, I thought it was an acerbation of my cataract. Some doctors mentioned eye nerve arthrosis!I smiled, I do not know anything about it, but I was wondering if such thing could even exist”.18 Discussion This review of 13 studies on the experience of patients with AMD receiving intravitreal anti-VEGF injections shows the complicated interplay between physiological, psychological and social factors of treatment perception. Unlike broader AMD reviews that include patients across all treatment stages, our meta-synthesis focusing exclusively on those receiving repeated intravitreal injections reveals that injected patients experience a higher intensity of psychological “burnout”. The results indicate that their psychological distress stems more from the treatment process itself, and therefore, compared with general AMD patients, this group demonstrates a significantly higher level of such burnout. The findings can be summarized into four main themes: barriers to treatment and sources of anxiety, coping strategies and adaptation mechanisms, drivers of treatment adherence, and the impact of doctor-patient engagement. The primary concern for most patients is injection-related anxiety. Anxiety arises from both the uncertainty of treatment process and potential side effects, as well as a direct fear of pain. The expected pain level during injection is significantly higher than the actual pain level,31 which leads some individuals to discontinue their treatment. Anxiety before treatment will lead to oversensitivity,32 which may affect the doctor’s procedure. For some patients, anxiety levels do not fade with repeated injections and may continue throughout the treatment period. This fear can linger even after doctors have explained the procedure’s safety profile and potential benefits.33 Clinicians should consider anxiety’s effect on treatment and include it in patient management. In addition, some practical measures, such as reasonable use of anesthetics34 and deep breathing exercises22 have been shown to effectively alleviate pain and fear, thereby improving treatment compliance and patient satisfaction. The psychological and cognitive challenges patients face can influence their subsequent treatment decisions. When the treatment process and results show positive outcomes, patients are more likely to view their course of treatment with optimism. Conversely, ambiguous information or uncertain results often create barriers to treatment adherence. By providing clear and thorough information, clinicians can counteract this uncertainty and guide patients toward realistic expectations.35 Furthermore, optimizing the care pathway itself can significantly enhance the patient experience, leading to improved treatment persistence and better outcomes.36 In summary, personal cognition is malleable core factor that buffers mental health and facilitate coping with chronic disease.37 The treatment process presents logistical and financial burdens for patients, adding to more complex psychological experiences. This is often reflected in prolonged waiting times, the burdens of costs and nursing, and difficult compromises to their daily lives. Research shows that approximately one-quarter of patients discontinue treatment due to these burdens.38 The influence of these factors and burdens on health equity present differently for different patient populations. Patients across different countries experience these challenges differently,39 while the key influencing factors ultimately arise from the core burdens previously described. While various strategies have been proposed to ease the treatment burden, implementing them presents significant challenges. The most promising approach involves developing treatments that require fewer injections40 and improve drug duration and efficacy, combined with coordinated solutions that address systemic barriers, such as transport and care access, thereby optimizing the long-term visual outcomes for all patients.14 Facing multiple challenges of treatment, patients respond in two distinct ways. Some respond positively, by adapting to the treatment regimen or revising their expectations. Others react negatively, experiencing a constriction of their lifestyle and a withdrawal from social connections. Crucially, a positive attitude on their disease and quality of life serves as a key driver of treatment adherence. Evidence indicates that a patient’ s adherence to treatment is shaped by a combination of internal and external factors. Internally, it involves their ability to confront the disease and treatment outcomes,41 and to adapt and use resources to maintain daily life.23 Externally, supportive relationships with family and clinicians, coupled with reliable healthcare and social services, can improve patient adherence.36 The clinical competence and communication skills of healthcare providers have a double impact. Inadequate clinical abilities and poor communication can aggravate the patient’s negative medical experience. Conversely, proficient clinicians who communicate effectively can foster greater patient trust, reduce anxiety21 and enhance treatment adherence.42 It is noteworthy that the relevant experience of the doctor–patient relationship has been mentioned many times in the studies included, which shows that despite the limited time in the medical environment, efficient and good communication strategies between medical staff and patients seem to be crucial to obtain a satisfactory diagnosis and treatment experience, so it needs to be paid attention to.24 Consequently, these findings underscore the importance of implementing standardized training programs to enhance both clinical communication skills and ensure maintenance of appropriate clinical competencies among healthcare providers. Limitations This study has several limitations. The included literature is limited to English, which predominantly comes from high-income countries. This creates a systematic bias, as these regions have greater research capacity and treatment resources compared to economically developing regions. Consequently, the findings may not be readily suitable for all environments. An additional concern is the lack of self-reflection in most studies on how the researchers’ cultural backgrounds and values might have exerted an unexamined influence on the research. Future research could address these limitations by incorporating studies in multiple languages, ensuring greater geographical and socioeconomic diversity, and employing longitudinal or mixed-methods designs. Conclusion In summary, this study reveals the experiences of AMD patients receiving intravitreal anti-VEGF injections. Our findings highlight that addressing the multifaceted challenges patients face, including psychological distress, logistical burdens, and communication gaps, is a clinical necessity for preventing treatment discontinuation and avoidable vision loss. Future research should consider expanding the scope of management, such as patient education programs, psychological support services, and specialized ophthalmic training. Integrating these findings operationalizes the patient-centered model, moving it from theory to practice.